Over the last decade, the development of targeted therapy has prompted efforts to genetically classify patients with lung carcinomas into subsets, such as epidermal growth factor receptor (EGFR)-mutated type [2][3], and anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged type [4]. The gene discussed is EGFR; the disease is lung carcinoma.